Sun Pharmaceutical announced its commitment to donate Rs 250 million of Hydroxychloroquine (HCQS), Azithromycin, other related drugs and hand sanitizers to support India’s COVID-19 pandemic response.
The press release also states that the company salutes the entire medical and support fraternity, including doctors, nurses and healthcare workers who are selflessly providing care to all affected patients in India. To help these front-line warriors, Sun Pharma has re-purposed its liquid manufacturing facility in India to produce high-quality hand sanitizers and will make them available to healthcare professionals serving their communities and the nation.
Sun Pharma is committed to fighting the COVID-19 pandemic and has instituted work from home for all team members who can work remotely at all its locations. The company urges people both in India and around the world not to hoard medicines, to make sure they are available to those in genuine need.
The company is committed to working closely with the governments and relevant stakeholders to ensure there is an uninterrupted supply of medicines. Sun Pharma is constituting a task force to handle the distribution of these products in India.
The National Task Force for COVID-19 has recommended the prophylactic use of HCQS for high-risk population. The approved indications of HCQS are malaria, lupus erythematosus and rheumatoid arthritis. The approved indications of Azithromycin are uncomplicated skin or skin structure infections, community-acquired pneumonia, and more. HCQS is currently being studied by the World Health Organization (WHO) for use in-conjunction with Azithromycin to treat COVID-19.
